Sarepta Therapeutics specializes in precision genetic medicines for rare neuromuscular diseases, with a flagship focus on Duchenne muscular dystrophy (DMD). It commercializes exon-skipping therapies that restore a truncated but functional dystrophin protein and has advanced gene therapy for DMD, notably ELEVIDYS. The company’s platform combines RNA-targeted phosphorodiamidate morpholino oligomers (PMOs) with AAV-based gene delivery. Its customers are largely patients and clinicians treating progressive muscle-wasting disorders with limited alternative treatments.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 611.1 | — | 196.9 | 373.4% |
| Q3 2025 | 399.4 | — | -179.9 | -404.3% |
| Q4 2025 | 442.9 | — | -282.9 | -255.8% |
| Q1 2026 | 730.8 | — | 331 | — |
| Q2 2026 | 401.3 | -34.3% | -4.9 | -102.5% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Chagee Holdings Limited (CHA), Clover Health Investments, Corp. (CLOV), The Andersons, Inc. (ANDE), Palvella Therapeutics, Inc. (PVLA), Interface, Inc. (TILE), Hycroft Mining Holding Corporation (HYMC)